
Opinion|Videos|August 16, 2024
The Role of Androgen Receptor-Targeted Therapy in the Treatment of mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore the role of androgen receptor-targeted therapy in mCRPC.
Advertisement
Episodes in this series

- How do androgen receptor-targeted therapies, including abiraterone and enzalutamide, fit into the treatment paradigm, and when might you choose an androgen receptor-targeted therapy over other treatment options, or vice versa?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5



















